[Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Modern data on biochemistry of fibrinolysis, molecular mechanisms for interaction of plasmin with fibrin and antiplasmins are discussed. Perspectives of thrombolytic therapy are considered. Evidence for selective action of plasmin, bound with alpha 2-macroglobulin, on fibrin offers new opportunities in research on newer effective thrombolytic drugs.
D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology*; D004800:Enzymes, Immobilized / Q000494:pharmacology / Q000627:therapeutic use; D005337:Fibrin / Q000494:pharmacology; D005340:Fibrinogen / Q000494:pharmacology; D005341:Fibrinolysin / Q000037:antagonists & inhibitors / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D046911:Macromolecular Substances; D008970:Molecular Weight; D010958:Plasminogen / Q000037:antagonists & inhibitors / Q000378:metabolism; D010960:Plasminogen Activators / Q000494:pharmacology*; D013300:Streptokinase / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D014357:Trypsin / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000494:pharmacology; D000511:alpha-Macroglobulins / Q000494:pharmacology
D000933:Antifibrinolytic Agents; D004800:Enzymes, Immobilized; D005343:Fibrinolytic Agents; D046911:Macromolecular Substances; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D014357:Trypsin; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator
Molekuliarnye mekhanizmy fibrinoliza i perspektivy tromboliticheskoĭ terapii (obzor).